Tilray Brands, Inc. (TLRY, Financial) recently experienced a significant stock movement, with its share price falling by 5.50%. The stock is currently priced at $1.03 per share, with a trading volume of approximately 38.29 million shares and a turnover rate of 4.10%. The company's recent financial report reveals an operating revenue of $211 million, a net loss of $85.34 million, and an earnings per share (EPS) of -$0.10. The gross profit stands at $38.29 million, resulting in a price-to-earnings (P/E) ratio of -3.51.
In terms of analyst ratings, 27% of the 15 institutions covering the stock recommend a buy, while 73% suggest holding, with no recommendations to sell. The broader pharmaceutical sector, where Tilray operates, saw a decline of 0.30%. Within this sector, stocks such as Im Cannabis Corp. and Organogenesis Holdings Inc. showed notable gains, while others like Dazhi Natural Medicine and Cbdmd, Inc. were more active with higher turnover rates.
Tilray, a Canadian producer, is involved in the cultivation and sale of cannabis for medical and recreational use. The company was formed after Aphria's reverse acquisition of legacy Tilray in 2021, focusing mainly on the Canadian market and international medical cannabis exports. In the U.S., its sales include cannabidiol (CBD) products and alcoholic beverages.
